Cutera has announced the internationally limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate and severe acne. AviClear is a 1726nm laser that targets and suppresses the production of sebum, treating acne at its source. It delivers high power (100W) selectively to the sebaceous glands, the source of sebum production while protecting surrounding tissue through Cutera’s AviCool contact cooling technology.
Related: Cutera Announces Over 1,000 AviClear Acne Treatments Performed
In an extensive clinical trial cited by Cutera, 92% of patients were deemed responders to the therapy (resolution of at least half of their acne), with a 79% median reduction in inflammatory lesion count at the 12-month mark following the final treatment.
Since its initial launch in North America, AviClear has been used to treat thousands of patients. The technology has received recognition from major beauty publications and garnered numerous awards, including Cosmopolitan’s 2023 Acne Award as Best Pro Treatment for Active Acne.
AviClear received an enthusiastic reception at this year’s International Master Course on Aging Science (IMCAS) conference in Paris, France. It was also featured in several acne-based sessions at IMCAS, including a presentation by dermatologist David J. Goldberg, M.D., who presented the results of 75 patients treated in his practice with AviClear following the FDA clearance in March 2022. Dr. Goldberg found similar results to the clinical trial.
Following IMCAS, AviClear is now commercially available, on a limited basis, in the U.K., Europe and Australia. Select practices will begin training on the technology in the coming weeks.
“AviClear represents a real step change in energy-based devices as a long-term treatment option for the management of acne," said cosmetic physician Tapan Patel, M.D., one of the first international AviClear providers. "The FDA clearance, long-term data and real-world results give practitioners confidence that this device offers something novel, effective, and durable."
“It was moving to witness the excitement surrounding AviClear at IMCAS. The amount of physician and patient interest we have received since its initial inception has been tremendous,” said Brent Hauser, international president of Cutera, Inc. “We are thrilled to be able to meet the broad demand for this type of treatment by steadily increasing availability and access globally.”
